MARKET

NBY

NBY

NOVABAY PHARMA
AMEX

Real-time Quotes | Nasdaq Last Sale

0.6400
+0.0310
+5.09%
After Hours: 0.6160 -0.024 -3.75% 19:44 09/21 EDT
OPEN
0.6090
PREV CLOSE
0.6090
HIGH
0.6672
LOW
0.6090
VOLUME
1.07M
TURNOVER
--
52 WEEK HIGH
1.790
52 WEEK LOW
0.5150
MARKET CAP
28.76M
P/E (TTM)
-3.1715
1D
5D
1M
3M
1Y
5Y
Contract Opportunity From Sam.gov Site Shows 'Notice of Intent- To Issue a Limited Sources Acquisition for Surgical Masks Manufactured in the U.S. or its Outlying Areas' From US Dept. Of Health & Human Services
https://sam.gov/opp/0274847a61aa44358282288d2e0a1bd3/view
Benzinga · 6h ago
Mask-Related Plays Move Higher; New York Governor Hochul Says Masks Required At State-Regulated Child Care Facilities
-Reuters
Reuters · 6d ago
Secretary of State for Health and Social Care of the United Kingdom Says Plan B Includes Legally Mandating Face Coverings In Some Settings
- Reuters
Reuters · 09/14 11:49
NovaBay Pharmaceuticals to Present at the H.C. Wainwright 23nd Annual Global Investment Conference
EMERYVILLE, Calif., September 08, 2021--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that management will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The company presentation wi...
Business Wire · 09/08 10:50
Illinois Governor Announces Statewide Indoor Mask Mandate
-Bloomberg
Bloomberg · 08/26 15:24
BRIEF-NovaBay Pharmaceuticals To Distribute Zocular Dry Eye Products
reuters.com · 08/19 11:17
NovaBay Pharmaceuticals to Distribute Zocular Dry Eye Products
NovaBay® Pharmaceuticals, Inc. (NYSE:NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zocular dry eye products
Benzinga · 08/19 10:55
NovaBay Pharmaceuticals to Distribute Zocular® Dry Eye Products
EMERYVILLE, Calif. & CYPRESS, Texas, August 19, 2021--NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a pharmaceutical company focusing on commercializing Avenova for the eye care market, announces an agreement with Okra Limited to distribute their Zo...
Business Wire · 08/19 10:50
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NBY. Analyze the recent business situations of NOVABAY PHARMA through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NBY stock price target is 2.700 with a high estimate of 3.500 and a low estimate of 1.900.
EPS
Institutional Holdings
Institutions: 20
Institutional Holdings: 647.60K
% Owned: 1.44%
Shares Outstanding: 44.94M
TypeInstitutionsShares
Increased
3
383.59K
New
7
174.48K
Decreased
6
97.70K
Sold Out
2
12.42K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.43%
Pharmaceuticals & Medical Research
+0.74%
Key Executives
Non-Executive Chairman/Independent Director
Paul Freiman
Chief Executive Officer/Chief Compliance Officer/General Counsel/Director/IR Contact Officer
Justin Hall
Chief Financial Officer/Treasurer
Andrew Jones
Director
Xinzhou Li
Director
Mijia Wu
Independent Director
Swan Sit
Independent Director
Yenyou Zheng
No Data
  • All
  • Financials
  • Insiders
More
About NBY
NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company, which develops products for the eye care market. The Company focuses on commercializing prescription Avenova for managing hygiene of the eyelids and lashes in the United States. Avenova is an eye care product formulated with a form of hypochlorous acid called Neutrox. Its Avenova with Neutrox removes debris from the skin on the eyelids and lashes without burning or stinging. It develops additional products containing Neutrox, including its NeutroPhase Skin and Wound Cleanser for wound care and CelleRx for the dermatology market. Its Aganocide compounds, led by auriclosene (NVC-422), are synthetic molecules with activity against bacteria, viruses and fungi. The Company's dermatology product includes CelleRx, a cleansing solution for post laser resurfacing, chemical peels and other cosmetic surgery procedures. Its wound care business includes the business of NeutroPhase product.

Webull offers kinds of NovaBay Pharmaceuticals, Inc. stock information, including AMEX:NBY real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NBY stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NBY stock methods without spending real money on the virtual paper trading platform.